Background
Methods
Study design and participants
Outcome measures
No prior CVD group (n = 1013) | Prior CVD group (n = 4996) | |||||
---|---|---|---|---|---|---|
Europe (n = 599) | USA (n = 414) |
P value | Europe (n = 2922) | USA (n = 2074) |
P value | |
Gender, female (n, %) | 223 (37.2) | 177 (42.8) | 0.077 | 857 (29.3) | 710 (34.2) | 0.001 |
Age, years (mean, SD) (n, %) | 66.0 (5.0) | 66.1 (5.6) | 0.783 | 64.6 (7.5) | 64.3 (7.7) | 0.166 |
50–59 | 10 (1.7) | 8 (1.9) | 798 (27.3) | 589 (28.4) | ||
60–69 | 454 (75.8) | 310 (74.9) | 1364 (46.7) | 971 (46.8) | ||
70–79 | 127 (21.2) | 84 (20.3) | 0.355 | 694 (23.8) | 451 (21.7) | 0.240 |
80–89 | 8 (1.3) | 12 (2.9) | 65 (2.2) | 62 (3.0) | ||
90–99 | 0 (0) | 0 (0) | 1 (0.0) | 1 (0.0) | ||
Diabetes duration, years (mean, SD) | 11.2 (6.8) | 13.2 (7.9) | <0.001
| 11.7 (7.6) | 13.5 (8.8) |
<0.001
|
Race (n, %) | ||||||
Asian | 3 (0.5) | 9 (2.2) | 25 (0.9) | 37 (1.8) | ||
Black | 2 (0.3) | 101 (24.4) | <0.001
| 14 (0.5) | 366 (17.6) |
<0.001
|
White | 592 (98.8) | 295 (71.3) | 2871 (98.3) | 1622 (78.2) | ||
Other | 2 (0.3) | 9 (2.2) | 12 (0.4) | 49 (2.4) | ||
Body weight, kg (mean, SD) | 94.0 (18.1) | 98.9 (23.4) | <0.001
| 93.6 (18.6) | 101.1 (21.8) |
<0.001
|
BMI, kg/m2 (mean, SD) (n, %) | 33.0 (5.6) | 34.4 (6.9) | <0.001
| 32.7 (5.8) | 34.6 (6.8) |
<0.001
|
18–25 | 25 (4.2) | 24 (5.8) | 181 (6.2) | 96 (4.6) | ||
25–30 | 176 (29.4) | 91 (22.0) | 843 (28.9) | 438 (21.1) | ||
30–35 | 216 (36.1) | 125 (30.2) | <0.001
| 1024 (35.0) | 686 (33.1) |
<0.001
|
35–40 | 113 (18.9) | 91 (22.0) | 554 (19.0) | 478 (23.0) | ||
>40 | 69 (11.5) | 83 (20.0) | 316 (10.8) | 375 (18.1) | ||
Waist circumference, cm (mean, SD) | 112.2 (15.5) | 114.1 (18.4) | 0.072 | 111.2 (15.3) | 114.5 (17.0) |
<0.001
|
HbA1c, % (mean, SD) | 8.4 (1.3) | 8.9 (1.6) | <0.001
| 8.3 (1.3) | 8.8 (1.5) |
<0.001
|
HbA1c at target (n, %) | ||||||
≤7.5 % | 186 (31.1) | 68 (16.4) | <0.001
| 880 (30.1) | 481 (23.2) | <0.001
|
≤7 % | 49 (8.2) | 18 (4.3) | 0.016 | 264 (9.0) | 157 (7.6) | 0.066 |
SBP, mmHg (mean, SD) | 144.1 (17.5) | 135.5 (17.1) | <0.001 | 140.0 (18.4) | 133.3 (18.5) | <0.001
|
DBP, mmHg (mean, SD) | 81.0 (9.7) | 76.0 (9.5) | <0.001
| 78.5 (10.2) | 74.7 (10.5) | <0.001
|
BP at target (n, %) (Europe < 140/80 and USA 130/80 mmHg) | 146 (24.4) | 134 (32.4) |
0.005
| 974 (33.3) | 800 (38.6) | <0.001
|
LDL, mmol/L (mean, SD) | 2.5 (0.9) | 2.3 (0.9) | <0.001
| 2.3 (0.9) | 2.2 (0.9) | 0.113 |
At target (n, %) | 319 (53.3) | 273 (65.9) | <0.001
| 1934 (66.2) | 757 (36.5) | <0.001
|
HDL, mmol/L (mean, SD) | 1.3 (0.3) | 1.2 (0.4) | 0.104 | 1.2 (0.3) | 1.2 (0.3) |
0.008
|
Triglyceride, mmol/L (mean, SD) | 2.0 (1.3) | 2.0 (2.0) | 0.749 | 2.1 (1.8) | 2.0 (1.5) | 0.038 |
Creatinine, μmol/L (mean, SD) | 71.6 (14.6) | 73.1 (15.6) | 0.106 | 85.4 (31.2) | 94.7 (38.2) | <0.001
|
ACR, mg/mmol (mean, SD) | 10.6 (30.5) | 14.8 (50.5) | 0.135 | 16.4 (57.3) | 26.5 (82.0) | <0.001
|
eGFR (mean, SD) | 90.0 (24.0) | 90.3 (20.5) | 0.847 | 81.3 (26.8) | 74.8 (27.1) | <0.001
|
Renal function, eGFR (mL/min/1.73 m2) (n, %) | ||||||
Normal (≥ 90) | 268 (44.7) | 181 (43.7) | 1079 (36.9) | 591 (28.5) | ||
Mild decline (60–90) | 331 (55.3) | 233 (56.3) | 0.748 | 1191 (40.8) | 809 (39.0) | <0.001
|
Moderate decline (30–60) | 0 (0.0) | 0 (0.0) | 605 (20.7) | 625 (30.1) | ||
Severe decline (< 30) | 0 (0.0) | 0 (0.0) | 47 (1.6) | 49 (2.4) | ||
Micro-albuminuria (n, %) | 246 (41.1) | 233 (56.3) | <0.001
| 347 (11.9) | 248 (12.0) | 0.930 |
Macro-albuminuria (n, %) | 31 (5.2) | 65 (15.7) | <0.001
| 77 (2.6) | 66 (3.2) | 0.253 |
Myocardial infarction (n, %) | 0 (0) | 0 (0) | 567 (19.4) | 321 (15.5) | <0.001
| |
Stroke (n, %) | 0 (0) | 0 (0) | 434 (14.9) | 289 (13.9) | 0.363 | |
Angina pectoris (n, %) | 0 (0) | 5 (0.8) | 0.062 | 1114 (38.1) | 617 (29.7) | <0.001
|
Arrhythmia (n, %) | 57 (9.5) | 45 (10.9) | 0.482 | 479 (16.4) | 394 (19.0) | 0.017 |
Left ventricle dysfunction (n, %) | 188 (31.4) | 56 (13.5) | <0.001
| 702 (24.0) | 379 (18.3) | <0.001
|
Smoking (n, %) | ||||||
Current | 83 (13.9) | 57 (13.8) | 407 (13.9) | 278 (13.4) | ||
Never | 248 (41.4) | 187 (45.2) | 0.455 | 946 (32.4) | 754 (36.4) | 0.013 |
Previous | 268 (44.7) | 170 (41.1) | 1569 (53.7) | 1042 (50.2) | ||
Pre-trial treatment (n, %) | ||||||
None/diet | 16 (2.7) | 41 (9.9) | 102 (3.5) | 226 (10.9) | ||
Insulin only | 19 (3.2) | 22 (5.3) | <0.001
| 200 (6.8) | 210 (10.1) | <0.001
|
OADs only | 380 (63.4) | 213 (51.4) | 1624 (55.6) | 973 (46.9) | ||
Insulin + OADs | 184 (30.7) | 138 (33.3) | 996 (34.1) | 665 (32.1) | ||
Number of oral blood glucose-lowering drugs (n, %) | ||||||
No OAD | 219 (36.6) | 201 (48.6) | 1298 (44.4) | 1101 (53.1) | ||
1 OAD | 155 (25.9) | 83 (20.0) | 0.424 | 707 (24.2) | 428 (20.6) | 0.013 |
2 OADs | 199 (33.2) | 109 (26.3) | 826 (28.3) | 463 (22.3) | ||
>2 OADs | 26 (4.3) | 21 (5.1) | 91 (3.1) | 82 (4.0) | ||
BP-lowering medication (n, %) | 517 (86.3) | 360 (87.0) | 0.767 | 2729 (93.4) | 1930 (93.1) | 0.639 |
Number of antihypertensive medications (n, %) | ||||||
0 | 82 (13.7) | 54 (13.0) | 193 (6.6) | 144 (6.9) | ||
1 | 225 (37.6) | 182 (44.0) | 0.018 | 731 (25.0) | 607 (29.3) |
0.001
|
2 | 172 (28.7) | 126 (30.4) | 1315 (45.0) | 920 (44.4) | ||
3 | 93 (15.5) | 44 (10.6) | 533 (18.2) | 324 (15.6) | ||
4 | 27 (4.5) | 8 (1.9) | 150 (5.1) | 79 (3.8) | ||
Statin (n, %) | 362 (60.4) | 298 (72.0) | <0.001
| 2369 (81.1) | 1704 (82.2) | 0.330 |
Other lipid-lowering drugs (n, %) | 2 (0.3) | 11 (2.7) |
0.001
| 39 (1.3) | 44 (2.1) | 0.032 |
Aspirin (n, %) | 192 (32.1) | 198 (47.8) | <0.001
| 1934 (66.2) | 1441 (69.5) | 0.014 |
Target levels
Statistical analyses
Results
Baseline differences between Europe and US patients: whole cohort
Baseline differences between Europe and US patients: group without prior CVD
Baseline differences between Europe and US patients: group with prior CVD
Participants with HbA1c at target
No prior CVD group (n = 1013) | Prior CVD group (n = 4996) | |||||
---|---|---|---|---|---|---|
Odds ratio | 95 % CI |
P value | Odds ratio | 95 % CI |
P value | |
Region (Europe as reference group) | 0.475 | 0.316; 0.704 | <0.001
| 0.762 | 0.647; 0.896 |
0.001
|
Age (per year) | 1.015 | 0.981; 1.050 | 0.393 | 1.032 | 1.020; 1.043 | <0.001
|
Sex (male as reference group) | 0.485 | 0.169; 1.271 | 0.148 | 0.834 | 0.685; 1.011 | 0.065 |
Diabetes duration (per year) | 0.976 | 0.951; 1.000 | 0.055 | 0.976 | 0.967; 0.986 | <0.001
|
Race (white as reference group) | ||||||
Asian | 0.970 | 0.139; 4.258 | 0.598 | 0.257; 1.223 | ||
Black | 1.691 | 0.672; 4.244 | 0.718 | 1.069 | 0.780; 1.452 | 0.266 |
Other | 1.358 | 0.195; 6.005 | 0.604 | 0.258; 1.248 | ||
Pre-trial diabetes treatment (none, diet as reference group) | ||||||
Insulin + OADs | 1.080 | 0.475; 2.710 | 0.800 | 0.586; 1.102 | ||
Insulin only | 0.956 | 0.272; 3.215 | 0.543 | 0.532 | 0.349; 0.805 | <0.001 |
OADs only | 1.365 | 0.629; 3.312 | 1.248 | 0.930; 1.693 | ||
BMI (18–25 as reference group) (kg/m2) | ||||||
25–30 | 0.628 | 0.286; 1.446 | 1.220 | 0.871; 1.730 | ||
30–35 | 0.788 | 0.369; 1.780 | 0.235 | 1.010 | 0.723; 1.427 | 0.049 |
35–40 | 0.619 | 0.273; 1.464 | 1.036 | 0.729; 1.488 | ||
>40 | 1.082 | 0.476; 2.575 | 0.824 | 0.561; 1.219 | ||
Creatinine, per μmol/L | 0.966 | 0.915; 1.015 | 0.179 | 0.998 | 0.993; 1.002 | 0.288 |
ACR, per mg/mmol | 1.002 | 0.997; 1.005 | 0.421 | 1.000 | 0.999; 1.002 | 0.471 |
eGFR, per mL/min/1.73 m2
| 0.967 | 0.931; 1.000 | 0.048 | 0.992 | 0.986; 0.998 |
0.007
|
Participants with BP at target
No prior CVD group (n = 1013) | Prior CVD group (n = 4996) | |||||
---|---|---|---|---|---|---|
Odds ratio | 95 % CI |
P value | Odds ratio | 95 % CI |
P value | |
Region (Europe as reference group) | 1.662 | 1.150; 2.402 |
0.007
| 1.314 | 1.136; 1.520 | <0.001
|
Age (per year) | 0.959 | 0.928; 0.990 |
0.009
| 0.992 | 0.982; 1.002 | 0.115 |
Sex (male as reference group) | 0.823 | 0.341; 1.707 | 0.641 | 1.070 | 0.901; 1.270 | 0.438 |
Diabetes duration (per year) | 1.020 | 0.998; 1.042 | 0.082 | 1.003 | 0.995; 1.012 | 0.472 |
Race (white as reference group) | ||||||
Asian | 1.758 | 0.457; 6.795 | 0.880 | 0.483; 1.560 | 0.064 | |
Black | 1.070 | 0.517; 2.318 | 0.604 | 0.724 | 0.551; 0.946 | |
Other | 0.442 | 0.063; 1.987 | 0.621 | 0.304; 1.189 | ||
BMI (18–25, reference group) ( kg/m2) | ||||||
25–30 | 1.217 | 0.577;2.677 | 0.889 | 0.655; 1.212 | ||
30–35 | 0.913 | 0.436;1.998 |
0.009
| 0.793 | 0.587; 1.077 |
0.008
|
35–40 | 0.511 | 0.229;1.177 | 0.693 | 0.503; 0.957 | ||
>40 | 0.650 | 0.283;1.533 | 0.623 | 0.442; 0.879 | ||
Number of antihypertensive medications | ||||||
0 (reference group) | ||||||
1 | 1.142 | 0.698; 1.897 | 0.918 | 0.693; 1.221 | ||
2 | 0.716 | 0.415; 1.244 | 0.096 | 1.010 | 0.772; 1.326 | <0.001
|
3 | 0.650 | 0.333; 1.256 | 0.648 | 0.477; 0.881 | ||
4 | 1.024 | 0.360; 2.670 | 0.646 | 0.424;0.975 | ||
Creatinine, per umol/L | 0.986 | 0.942; 1.021 | 0.488 | 1.004 | 1.000; 1.008 | 0.058 |
ACR, per mg/mmol | 0.992 | 0.983; 0.999 | 0.013 | 0.994 | 0.992; 0.996 | <0.001
|
eGFR,per mL/min/1.73 m2
| 0.985 | 0.956; 1.007 | 0.239 | 0.998 | 0.992; 1.003 | 0.334 |
Micro-albuminuria | 0.895 | 0.628; 1.275 | 0.538 | 0.947 | 0.774; 1.155 | 0.592 |
Macro-albuminuria | 0.918 | 0.507; 1.635 | 0.775 | 1.562 | 1.060; 2.287 | 0.024 |
Participants with LDL at target
No prior CVD group (n = 1013) | Prior CVD group (n = 4996) | |||||
---|---|---|---|---|---|---|
Odds ratio | 95 % CI |
P value | Odds ratio | 95 % CI |
P value | |
Region (Europe as reference group) | 1.616 | 1.116; 2.355 | 0.011 | 0.248 | 0.212; 0.290 | <0.001
|
Age (per year) | 1.038 | 1.006; 1.072 | 0.020 | 1.012 | 1.001; 1.023 | 0.032 |
Sex (male as reference group) | 0.542 | 0.311; 1.009 | 0.053 | 0.535 | 0.444; 0.644 | <0.001
|
Diabetes duration (per year) | 1.011 | 0.989; 1.035 | 0.330 | 1.004 | 0.995; 1.013 | 0.358 |
Race (white as reference group) | ||||||
Asian | 0.632 | 0.136; 3.479 | 1.226 | 0.664; 2.275 | ||
Black | 0.710 | 0.371; 1.339 | 0.633 | 0.773 | 0.581; 1.023 | 0.226 |
Other | 1.53 | 0.313; 8.783 | 0.759 | 0.389; 1.451 | ||
BMI (18–25, reference group) (kg/m2) | ||||||
25–30 | 0.571 | 0.239; 1.298 | 1.029 | 0.735; 1.438 | ||
30–35 | 0.836 | 0.353; 1.884 | 0.224 | 1.083 | 0.778; 1.503 | 0.472 |
35–40 | 0.879 | 0.361;2.049 | 1.105 | 0.782; 1.560 | ||
>40 | 0.935 | 0.375; 2.246 | 1.287 | 0.891; 1.856 | ||
Statin use (no as reference) | 4.669 | 3.352; 6.550 | <0.001
| 4.276 | 3.526; 5.202 | <0.001
|
Aspirin use (no as reference) | 1.055 | 0.750; 1.482 | 0.759 | 1.369 | 1.174; 1.597 | <0.001
|
Creatinine, per umol/L | 1.007 | 0.982; 1.038 | 0.607 | 0.995 | 0.991; 1.000 | 0.034 |
ACR, per mg/mmol | 0.999 | 0.995; 1.003 | 0.485 | 0.999 | 0.997; 1.000 | 0.017 |
eGFR per mL/min/1.73 m2
| 1.006 | 0.993; 1.025 | 0.360 | 0.994 | 0.988; 1.000 | 0.036 |